Second phase I abuse liability trial of intranasally administered benzhydrocodone/paracetamol (KP 201)
Phase of Trial: Phase I
Latest Information Update: 05 May 2016
At a glance
- Drugs Benzhydrocodone/paracetamol (Primary) ; Hydrocodone/paracetamol
- Indications Pain
- Focus Adverse reactions
- 05 May 2016 According to a KemPharm media release, the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US FDA voted in favor of approval for benzhydrocodone/paracetamol hydrochloride combination (Apadaz) for the management of acute pain that requires opioid and voted against inclusion of abuse deterrent labeling for the product.
- 14 Mar 2016 According to a KemPharm Inc. media release, the company's NDA for benzhydrocodone/paracetamol (KP201/APAP) was accepted and granted priority review by the FDA in early February 2016. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 9, 2016.
- 12 Nov 2015 According to KemPharm Inc. media release, In May 2015 the company obtained guidance in a pre-NDA meeting with the FDA.